Dilated Cardiomyopathy

  • Yoshifumi Hamasaki


  • Autoimmune disorders are considered to be one of the causes of dilated cardiomyopathy (DCM). Immunoglobulin G3 subclass antibodies are suggested to play a role in the pathogenesis of DCM.

  • Immunoadsorption plasmapheresis (IAPP) is a therapeutic apheresis treatment for DCM.

  • Because angiotensin converting enzyme inhibitor (ACE-I) drugs are contraindicated when IAPP with Imsorba® is performed, ACE-I therapy should be discontinued or switched to other drugs, such as an angiotensin II receptor blocker, before starting IAPP.


Dilate Cardiomyopathy Angiotensin Converting Enzyme Inhibitor Adsorption Column Angiotensin Converting Enzyme Inhibitor Therapy Therapeutic Apheresis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Miura K et al (2002) Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart 87(2):126–130PubMedCrossRefGoogle Scholar
  2. 2.
    Yoshikawa T et al (2009) Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 73:602–607PubMedCrossRefGoogle Scholar
  3. 3.
    Felix SB et al (2008) Immunoadsorption as treatment option in dilated cardiomyopathy. Autoimmunity 41(6):484–489PubMedCrossRefGoogle Scholar
  4. 4.
    Staudt A et al (2010) Fc gamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin Pharmacol Ther 87(4):452–458PubMedCrossRefGoogle Scholar
  5. 5.
    Wallukat G et al (1996) Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 54(2):191–195PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.22nd Century Medical and Research CenterThe University of Tokyo HospitalTokyoJapan

Personalised recommendations